

**Nombre:** Luis Alejandro Pérez de Llano.

-Licenciado en Medicina por la Facultad de Santiago de Compostela (1989)

-Neumólogo (residencia en el H Marqués de Valdecilla, 1995).

-Doctor en Medicina y Cirugía por la Universidad de Cantabria (2006).

-Máster en Dirección de Unidades de Gestión Clínica por la UCAM (2014).

**Cargos:**

-Jefe de Servicio de Neumología del HULA desde el año 2005. Lugo.

-Patrono de la Fundación Ramón Domínguez.

-Presidente del Comité de Investigación del Hospital Lucus Augusti.

-Director del PII de Asma de SEPAR desde Junio del 2018.

**Áreas de interés:**

-Investigación clínica en asma.

-Investigación clínica en ventilación no invasiva.

**Estudios activos en los que he participado como promotor:**

-Estudio ATAUD para conocer si el cumplimiento de la medicación para el asma es mejor con una dosificación al día que con dos (finalizado y enviado para publicación).

-Estudio ENEAS para conocer las necesidades clínicas no cubiertas en pacientes con asma grave en España (fase de reclutamiento).

-Ensayo clínico SEP-RES 2016-01 para estudiar la efectividad del reslizumab en pacientes con asma grave que han sido tratados previamente con omalizumab y este tratamiento fracasó (reclutamiento finalizado).

-Estudio CHACOS para caracterizar el overlap asma-EPOC. En revisión las dos últimas publicaciones.

### Últimas publicaciones:

1. Omalizumab therapy in severe asthma: experience from the Spanish registry-- some new approaches. Vennera Mdel C, Pérez De Llano L, Bardagí S, Ausin P, Sanjuas C, González H, Gullón JA, Martínez-Moragón E, Carretero JA, Vera E, Medina JF, Alvarez FJ, Entrenas LM, Padilla A, Irigaray R, Picado C; Spanish Registry. *J Asthma*. 2012 May;49(4):416-22.
2. Involvement of Spanish pulmonology centers in patient care, postgraduate education and research in asthma: the results of the ATENEA survey. Plaza V, Bellido-Casado J, Díaz C, Pérez de Llano L, Sanchis J, Villasante C, López Viña A. *Arch Bronconeumol*. 2012 Apr;48(4):114-9.
3. Nitric oxide (NO) in managing asthma. Pérez de Llano LA. *Arch Bronconeumol*. 2012; 48(2):35-6.
4. Effects of omalizumab in Aspergillus-associated airway disease. Pérez-de-Llano LA, Vennera MC, Parra A, Guallar J, Marin M, Asensio O, Ausin P, Borderías L, Fernández C, Granel C, Pérez-Pimiento A, Rubio M. *Thorax*. 2011; 66(6): 539-40.
5. Haemodynamic effects of non-invasive ventilation in patients with obesity-hypoventilation syndrome. Castro-Añón O, Golpe R, Pérez-de-Llano LA, López González MJ, Escalona Velasquez EJ, Pérez Fernández R, Testa Fernández A, González Quintela A. *Respirology*. 2012; 17(8): 1269-74.
6. Golpe R, Sanjuán López P, Cano Jiménez E, Castro Añón O, Pérez de Llano LA. Distribution of clinical phenotypes in patients with chronic obstructive pulmonary disease caused by biomass and tobacco smoke. *Arch Bronconeumol*. 2014 ; 50(8): 318-24.
7. Castro-Añón O, Pérez de Llano LA, De la Fuente Sánchez S, Golpe R, Méndez Marote L, Castro-Castro J, González Quintela A. Obesity-hypoventilation syndrome: increased risk of death over sleep apnea syndrome. *PLoS One*. 2015; 10(2): e0117808.
8. Cisneros Serrano C, Melero Moreno C, Almonacid Sánchez C, Perpiñá Tordera M, Picado Valles C, Martínez Moragón E, Pérez de Llano L, Soto Campos JG, Urrutia Landa I, García Hernández G. Guidelines for Severe Uncontrolled Asthma. *Arch Bronconeumol*. 2015; 51(5): 235-246.

9. Pérez de Llano LA, García Rivero JL, Pallares A, Mengual N, Golpe R. Cortico-dependent Asthma: Our Clinical Experience. *Arch Bronconeumol*. 2015 Apr 21.
10. Golpe R, Mengual-Macénlle N, Sanjuán-López P, Cano-Jiménez E, Castro-Añón O, Pérez-de-Llano LA. Prognostic Indices and Mortality Prediction in COPD Caused by Biomass Smoke Exposure. *Lung*. 2015 Apr 30.
11. Plaza V, Fernández-Rodríguez C, Melero C, Cosío BG, Entrenas LM, Pérez de Llano L, Gutiérrez-Pereyra F, Tarragona E, Palomino R, López-Viña A. Validation of the 'Test of the Adherence to Inhalers' (TAI) for Asthma and COPD Patients. *J Aerosol Med Pulm Drug Deliv*. 2015 Jul 31.
12. Miravittles M, Alcázar B, Alvarez FJ, Bazús T, Calle M, Casanova C, Cisneros C, de-Torres JP, Entrenas LM, Esteban C, García-Sidro P, Cosio BG, Huerta A, Iriberry M, Izquierdo JL, López-Viña A, López-Campos JL, Martínez-Moragón E, Pérez de Llano L, Perpiñá M, Ros JA, Serrano J, Soler-Cataluña JJ, Torrego A, Urrutia I, Plaza V. What pulmonologists think about the asthma-COPD overlap syndrome. *Int J Chron Obstruct Pulmon Dis*. 2015; 10: 1321-30.
13. Pérez de Llano LA, Villoro R, Merino M, Gómez Neira MD, Muñiz C, Hidalgo Á. Cost Effectiveness of Outpatient Asthma Clinics. *Arch Bronconeumol*. 2015 Nov 5. pii: S0300-2896(15)00376-2.
14. Quality indicators of asthma care derived from the Spanish guideline for asthma management (GEMA 4.0): A multidisciplinary team report. Quirce S, Delgado J, Entrenas JL, Grande M, Llorente C, López Viña A, Martínez Moragón E, Mascarós E, Molina J, Olaguibel JM, Pérez de Llano LA, Perpiñá Tordera M, Quintano JA, Rodríguez M, Román-Rodríguez M, Sastre J, Trigueros JA, Valero AL, Zoni AC, Plaza V; ASMAFORUM II Group. *J Investig Allergol Clin Immunol*. 2016 Nov 11:0. doi: 10.18176/jiaci.0121
15. Excessive variability in the performance and interpretation of the metacholine bronchial challenge test. Martínez Moragón E, Pérez de Llano L, Perpiñá M. *Arch Bronconeumol*. 2016; 52(11): 574.
16. Clinical significance of the oral corticosteroid reversibility test in asthma with fixed airflow obstruction. Riaño Pérez A, Pérez de Llano LA, Mengual N, Golpe R. *Arch Bronconeumol*. 2017; 53(1) :40.

17. Blood Pressure Profile and Hypertensive Organ Damage in COPD Patients and Matched Controls. The RETAPOC Study. Golpe R, Mateos-Colino A, Testa-Fernández A, Pena-Seijo M, Rodríguez-Enríquez M, González-Juanatey C, Martín-Vázquez FJ, Pose-Reino A, Domínguez-Pin N, Garnacho-Gayarre N, Pérez-de-Llano LA. PLoS One. 2016; 11(6): e0157932.
18. Asthma, Chronic Obstructive Pulmonary Disease and Other Combinations. Pérez de Llano LA, Cosío BG. Arch Bronconeumol. 2016; 52(10): 499-500.
19. Cost-effectiveness of Continuous Positive Airway Pressure Treatment in Moderate-Severe Obstructive Sleep Apnea Syndrome. Català R, Villoro R, Merino M, Sangenís S, Colomé L, Hernández Flix S, Pérez de Llano LA. Arch Bronconeumol. 2016; 52(9): 461-9.
20. Pérez de Llano LA, Cosío BG. Asthma, Chronic Obstructive Pulmonary Disease and Other Combinations. Arch Bronconeumol. 2016; 52(10): 499-500.
21. Golpe R, Mateos-Colino A, Testa-Fernández A, Pena-Seijo M, Rodríguez-Enríquez M, González-Juanatey C, Martín-Vázquez FJ, Pose-Reino A, Domínguez-Pin N, Garnacho-Gayarre N, Pérez-de-Llano LA. Blood Pressure Profile and Hypertensive Organ Damage in COPD Patients and Matched Controls. The RETAPOC Study. PLoS One. 2016; 11(6): e0157932.
22. Golpe R, Martín-Robles I, Sanjuán-López P, Cano-Jiménez E, Castro-Añón O, Mengual-Macén N, Pérez-de-Llano L. Prevalence of Major Comorbidities in Chronic Obstructive Pulmonary Disease Caused by Biomass Smoke or Tobacco. Respiration. 2017 Apr 29. doi: 10.1159/000472718.
23. Cosío BG, Pérez de Llano L, Lopez Viña A, Torrego A, Lopez-Campos JL, Soriano JB, Martínez Moragón E, Izquierdo JL, Bobolea I, Callejas J, Plaza V, Miravittles M, Soler-Catalunya JJ; on behalf of the CHACOS study group. Th-2 signature in chronic airway diseases: towards the extinction of asthma-COPD overlap syndrome? Eur Respir J. 2017 May 1;49(5). pii: 1602397.
24. Miravittles M, Alvarez-Gutierrez FJ, Calle M, Casanova C, Cosío BG, López-Viña A, Pérez de Llano L, Quirce S, Roman-Rodríguez M, Soler-Cataluña JJ, Plaza V. Algorithm for identification of asthma-COPD overlap: consensus between the Spanish COPD and asthma guidelines. Eur Respir J. 2017 May 1;49(5). pii: 1700068.

25. Plaza V, Álvarez F, Calle M, Casanova C, Cosío BG, López-Viña A, Pérez de Llano L, Quirce S, Román-Rodríguez M, Soler-Cataluña JJ, Miravittles M. Consensus on the Asthma-COPD Overlap Syndrome (ACOS) Between the Spanish COPD Guidelines (GesEPOC) and the Spanish Guidelines on the Management of Asthma (GEMA). *Arch Bronconeumol*. 2017 May 8. pii: S0300-2896(17)30092-3.
26. Palomares Ó, Sánchez-Ramón S, Dávila I, Prieto L, Pérez de Llano L, Leonart M, Domingo C, Nieto A. dIvergEnt: How IgE Axis Contributes to the Continuum of Allergic Asthma and Anti-IgE Therapies. *Int J Mol Sci*. 2017 Jun 21;18(6). pii: E1328.
27. Nieto Cano S, Golpe Gómez R, Pérez de Llano LA. The Need for Palliative Care in Chronic Respiratory Patients With Non-Malignant Disease. *Arch Bronconeumol*. 2017 Sep 14. pii: S0300-2896(17)30275-2.
28. Golpe R, Martín-Robles I, Sanjuán-López P, Pérez-de-Llano L, González-Juanatey C, López-Campos JL, Arellano-Orden E. Differences in systemic inflammation between cigarette and biomass smoke-induced COPD. *Int J Chron Obstruct Pulmon Dis*; 12: 2639-2646.
29. Pérez-de-Llano L, Cosío BG; CHACOS study group. Asthma-COPD overlap is not a homogeneous disorder: further supporting data. *Respir Res*. 2017; 18(1): 183.
30. de Llano LP, Cosío BG, Iglesias A, de Las Cuevas N, Soler-Cataluña JJ, Izquierdo JL, López-Campos JL, Calero C, Plaza V, Miravittles M, Torrego A, Martínez-Moragon E, Soriano JB, Viña AL, Bobolea I. Mixed Th2 and non-Th2 inflammatory pattern in the asthma-COPD overlap: a network approach. *Int J Chron Obstruct Pulmon Dis*. 2018; 13: 591-601.
31. Pérez de Llano L, López-Campos JL, Cosío BG. The post-truth behind the asthma-COPD overlap and the orbit of Mercury: lessons from the CHACOS study. *Arch Bronconeumol* 2018; 54(4): 175-176.
32. Golpe R, Sanjuán-López P, Martín-Robles I, González-Juanatey C, Pérez-de-Llano L, López-Campos JL. Cardiovascular Studies in Patients with Chronic Obstructive Pulmonary Disease Due to Biomass Smoke or Tobacco. *Lung*. 2018; 196(2): 195-200.

33. Golpe R, Suárez-Valor M, Castro-Añón O, Pérez-de-Llano LA. Risk Stratification in Chronic Obstructive Pulmonary Disease. Can the Spanish Guidelines be Improved? *Arch Bronconeumol*. 2018. pii: S0300-2896(18)30050-4.
34. Golpe R, Suárez-Valor M, Martín-Robles I, Sanjuán-López P, Cano-Jiménez E, Castro-Añón O, Pérez de Llano LA. Mortality in COPD patients according to clinical phenotypes. *Int J Chron Obstruct Pulmon Dis* 2018; 13: 1433-1439.
35. Pérez de Llano L, Cosío BG, Miravittles M, Plaza V; CHACOS study group. Accuracy of a New Algorithm to Identify Asthma-COPD Overlap (ACO) Patients in a Cohort of Patients with Chronic Obstructive Airway Disease. *Arch Bronconeumol* 2018; 54(4): 198-204.
36. Bulathsinhala L, Eleangovan N, Heaney LG, Menzies-Gow A, Gibson PG, Peters M, Hew M, van Boven JFM, Lehtimäki L, van Ganse E, Belhassen M, Harvey ES, Perez de Llano L, Maitland-van der Zee AH, Papadopoulos NG, FitzGerald JM, Porsbjerg C, Canonica GW, Backer V, Rhee CK, Verhamme KMC, Buhl R, Cosio BG, Carter V, Price C, Le T, Stagno d'Alcontres M, Gopalan G, Tran TN, Price D. Development of the International Severe Asthma Registry (ISAR): A Modified Delphi Study. *J Allergy Clin Immunol Pract*. 2018 Sep 1. pii: S2213-2198(18)30552-X.
37. Cosío BG, Dacal D, Pérez de Llano L. Asthma-COPD overlap: identification and optimal treatment. *Ther Adv Respir Dis*. 2018 Jan-Dec; 12:1753466618805662.
38. Pérez de Llano L, García-Rivero JL, Urrutia I, Martínez-Moragón E, Ramos J, Cebollero P, Carballada F, Blanco M, Vennera MDC, Merino M, García Nr YT, Plaza V. A simple score for future risk prediction in patients with controlled asthma who undergo a guidelines-based step-down strategy. *J Allergy Clin Immunol Pract*. 2018. pii: S2213-2198(18)30674-3.
39. Golpe R, Suárez-Valor M, Veiga-Teijeiro I, Veres-Racamonde A, Pérez-de-Llano LA. Should Lung Function Be Included in the Risk Stratification of Chronic Obstructive Pulmonary Disease Proposed by GesEPOC? *Arch Bronconeumol*. 2019 Jan 11. pii: S0300-2896(18)30471-X. doi: 10.1016/j.arbres.2018.12.007.
40. Pérez de Llano et al. Efficacy and safety of reslizumab in severe asthma patients with inadequate response to omalizumab: a multicentre, open-label, pilot study. *J Allergy Clin Immunol Pract*. 2019. In press.

Lugo a 16 de Enero del 2019

A handwritten signature in black ink, consisting of several overlapping, fluid strokes that form a cursive, somewhat abstract shape. The signature is positioned horizontally and appears to be written on a light-colored, textured background.